Zosano Pharma Corp.'s migraine-targeting zolmitriptan-coated microneedle patch, M207, met both co-primary endpoints of the company's pivotal phase III Zotrip trial, delivering freedom from pain at two hours for 41.5 percent of treated patients and relieving the most bothersome symptom for a majority of those treated at the same time point.